Clinical trials located in

Wałbrzych

Wałbrzych city is located in Poland. Currently, 6 clinical trials are being conducted in this city.

Wałbrzych, located in southwestern Poland, is a city steeped in history and natural beauty. Once a thriving coal mining center, it has transformed into a cultural hub, boasting the majestic Książ Castle, Poland’s third-largest castle, nestled amidst the lush Wałbrzych Mountains. The city is also known for its well-preserved underground tunnels, rumored to hide WWII treasures. Wałbrzych’s urban landscape is adorned with historic buildings, reflecting its rich industrial past. Additionally, it serves as a gateway to the scenic Sudetes range, offering a blend of historical intrigue and natural wonders.

  • CT-EU-00116303

    Study of SLN124 for treatment of Polycythemia Vera

    This here clinical trial is aimin’ to study a new drug called SLN124 for folks with Polycythemia Vera, which is a type of blood disorder. SLN124 is a special kind of molecule that targets a specific messenger in the body that’s involved in this condition.

    The trial has two parts. First, they’ll be testin’ different doses of SLN124 to find the right amount that’s safe and well-tolerated. Thereafter, they’ll have a bigger group of patients, with some gettin’ the real SLN124 and others gettin’ a placebo. This second part will be double-blind, meanin’ neither the patients nor the doctors know who’s gettin’ the real drug.

    The main things they’ll be lookin’ at are any side effects or safety issues with SLN124, and how well it works at reducin’ the need for phlebotomies, which are those blood removal procedures that Polycythemia Vera patients often need. They’ll be keepin’ a close eye on folks for almost a year to check how the drug is workin’ and make sure it’s safe.

    • SLN124
    • placebo
  • Study on luspatercept treatment for Myelodysplastic Syndrome

    This study is looking into a medication named Luspatercept and how safe and effective it is for people who have a blood condition known as lower-risk Myelodysplastic Syndrome, or LR-MDS for short. These individuals often need transfusions or have their blood refreshed with new, healthy red blood cells. The drug will be given at its highest approved dose to see what effect it has. This is being done in a controlled and careful way to make sure everything is safe for the participants in the study. People who are taking part in this study have been identified as having a very low to medium risk according to the International Prognostic Scoring System (IPSS-R). This means their disease isnt considered high-risk, which makes them suitable candidates for this research. The study is open-label, meaning everybody knows what is in the drug they are getting.

    • Luspatercept
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in Poland:

.